Elder Pharmaceuticals Ltd vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of Elder Pharmaceuticals Ltd (ELDERPHARM) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads ELDERPHARM vs TORNTPHARM on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth01
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
78.03
0.00
P/B ratio
18.67
0.00%
Dividend yield
0.76%
₹-3.18
EPS
₹63.92

Profitability

TORNTPHARM takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-45.60%
Return on equity
27.40%
-4.00%
Return on capital
15.00%
-44.00%
EBITDA margin
33.00%
-0.70%
Net margin
15.29%

Growth

TORNTPHARM takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

1.27%
Revenue CAGR (3Y)
13.27%
Profit CAGR (3Y) even
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹0 Cr
Market cap
₹1.88L Cr
₹997 Cr
Revenue
₹13,980 Cr
₹-7 Cr
Net profit
₹2,138 Cr
0.00
Debt / equity
1.69
Elder Pharmaceuticals Ltd
  • + ["Company has reduced debt.", "Stock is trading at 0.11 times its book value", "Debtor days have improved from 81.3 to 60.7 days."]
  • ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of 9.95% over past five years.", "Company has a low return on equity of -9.04% over last 3 years.", "Contingent liabilities of Rs.161 Cr.", "Company's cost of borrowing seems high"]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
Elder Pharmaceuticals Ltd full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

ELDERPHARM vs TORNTPHARM: Share Price, Valuation & Which to Buy | DocStoX